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227 and 440. Bridge to transplantation has been a scenario for the use of a varietyof mechanical support devices since the mid-1980s. Nearly everydevice studied led to survival to transplantation in the range of 60%to 70% and survival to discharge after transplantation of 50% to60% of the total population. Selection has not been standardized,but in general the patient population, in the absence of device
support, has been at very high risk. Several thousand lives have been saved, and
much experience has been gained in the use of artificial hearts, left ventricular assist
devices (LVADs), and biventricular assist devices (BiVADs). This experience will
lead to future use of mechanical support devices as permanent definitive therapy for
a population of patients with heart failure in the United States that has most often
been estimated to be in the range of 30,000 to 60,000 patients per year. Definitive
use of device support is underway in small numbers of patients and appears very
promising. Bridge to transplant studies such as the report by Frazier and associates1
in this Journal are therefore of vital concern to the thoracic surgery community.
The report by Frazier and colleagues1 of 280 implants of the HeartMate vented
electric LVAD (Thermo Cardiosystems, Inc, Woburn, Mass) at 24 centers in the
United States represents a major effort by a group of excellent surgeons. It docu-
ments that, of the total number of patients, 67% survived to transplantation and 56%
(84% of those undergoing transplantation) lived for at least 1 year after transplan-
tation compared with 33% survival to transplant and 21% (63% of those trans-
planted) survival for 1 year after transplantation in a group of 48 matched historical
controls. “Outpatient enrollment” for implanted patients was 70% (160 patients) and
“full outpatient status” was attained by 41% (115 patients), demonstrating that
out-of-hospital life was possible in a large proportion of the study group. For these
reasons, it must be regarded as an important study supporting the concept of bridge
to transplantation and the promise of using mechanical support devices as alterna-
tives to transplantation. But, like many previous sponsored mechanical support
device studies, it suffers from imperfections that result from study design and
incomplete information and thus at once tantalizes and frustrates the critical reader.
To encourage such readers to be more accepting of the truths of this article and
aware of the shortcomings, I propose a review of some of the limitations of this and
other “artificial heart” studies.
First there is the problem of “a controlled study.” The current “evidence based”
practice of medicine and surgery is founded on the randomized prospective trial.
The Food and Drug Administration (FDA) has reluctantly accepted historical
controls, such as those used in this study, in bridge to transplant studies. The ethical
problem in mechanical support device research has been that the surgeon, who is
trying to maximize benefit and minimize risk in his critically ill patient, cannot ask
such a patient to be randomized to the non-device group. This is especially true the
sicker the patient becomes and the more positive the surgeon is of the benefit of his
device and ultimate goal (bridge to transplantation). It is less true in more stable
patients with less well-defined goals. For instance, in this study, with patients
receiving the implant having a mean cardiac index of 1.67 L  min1  m2, a
systolic blood pressure of 75 mm Hg, a wedge pressure of 27 mm Hg, and all
patients having maximal inotropic support with 49% on intra-aortic balloon pump-
ing, the principal investigators would effectively be asking 50% of their patients to
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make the “ultimate sacrifice” for the sake of a controlled
study while the other 50% would have a reasonable chance
of going on to heart transplantation. In contrast, the ran-
domized REMATCH trial is enrolling functional class IV
patients who are more stable.2 In this group of patients who
are not transplant candidates, randomization is ethically
reasonable since the outcome for continued medical therapy
versus definitive device therapy is unknown.
It is not surprising to the clinician that there was a huge
difference in survival in this report between the treated
patients and the historical controls because he or she is
experienced enough to know that the mortality in these very
sick patients is very high. Two other previously published
multicenter bridge to transplant studies of devices (Nova-
cor3 [Baxter Healthcare Corp, Novacor Div, Oakland, Calif]
and CardioWest4 [CardioWest Technologies, Inc, Tucson,
Ariz]) used historical controls. They, too, found highly
significant survival differences favoring the patients receiv-
ing the device. Although the science of these studies is
imperfect, the benefit of these devices in prolonging life is
as certain as we can make it.
Definition and interpretation of “adverse events” is an-
other stumbling block in artificial heart papers. Frazier’s
report states that patients “had an acceptably low incidence
of adverse events.” It goes on to say, “. . . our assignment of
adverse events to the device or to the patient in this study
was subjective . . . ,” but they did report the total incidence
of events according to the definitions set by the study.
If we look at bleeding as an example, the problems of
definition and interpretation become evident. In this study,
the adverse event “bleeding” is defined as requiring a re-
exploration or causing death. Volumes and rates of blood
loss are not quantitated. Thus, lesser amounts of blood loss,
which may have been significant, are ignored. Of 280 pa-
tients, 133 (48%) met the adverse event definition of bleed-
ing. Eighty-three percent of the “bleeding” was during the
first 5 postimplant days. Device-related bleeding (coming
from the device or the pocket) was reported in 31 patients
(11%). What does this say? As the authors noted, “the
incidence of bleeding was relatively high.” Given the study
definition that ignores rate of bleeding or total volume of
bleeding, it must be concluded that bleeding is a significant
problem in this study. One can only guess what a more
inclusive definition might have yielded. Sixty percent would
be a conservative guess.
Was all of this bleeding solely because of the severity of
patient disease, or could it be related to the device itself?
Device-related bleeding is rarely mentioned in other reports,
yet it accounts for nearly one fourth of the bleeding in this
study. Whether one agrees with the reporting definitions or
the subjective division between device related and not de-
vice related that is mandated by the FDA, it is clear in this
report that bleeding is a problem and that it may be related
to the device. The Columbia group found evidence of a “low
grade DIC” (increased thrombin generation and fibrinolysis)
in HeartMate patients compared with heart failure patients
and concluded that there was therefore a potential for in-
creased bleeding.5 This then leads to speculation that if the
“biologic neoinitma” of the HeartMate device confers a
status that discourages thromboembolism, that is, creates a
“hypocoagulable” state at the time of implantation, would
this explain the increased bleeding? We do not know the
answer to this complex question and have little information
to interpret other questions that arise.
Was this bleeding excessive? The Novacor FDA study,6
using a broader definition of bleeding, reported a 39.7%
total incidence and, also using a broader definition, the
CardioWest national study found a 33% total incidence of
bleeding.4 Both of these are considerably lower than the
narrowly defined 48% in this study. Notwithstanding these
numbers, an independent retrospective comparison of sig-
nificant numbers of Thoratec, Novacor, and HeartMate im-
plantations failed to show any significant difference among
those 3 devices in perioperative bleeding. Unfortunately,
bleeding was not formally defined in that study.7 No other
comparative study has been done.
Our analysis of the bleeding adverse event in this report
leads to a general impression and a number of unanswered
questions that were not part of the original investigational
device exemption (IDE) study. So it is with many of the
other adverse events in this and other IDE reports. The
studies were designed to define efficacy and safety long
before the data were available to provoke a host of new
questions. To further look into the bleeding question will
require additional studies.
Other adverse events that seem important in this report
include the high rate of driveline infections (90 patients,
32%). A report from Cleveland found 28% of HeartMate
patients had driveline infections.8 The issue of the effect of
this device with “biologic lining” on the inflammatory and
immune systems and consideration of other factors that
might cause driveline infections were not directly ad-
dressed. One is again left with a nagging question.
Finally, the large number (435 events or 1.2 per 100 days
of support) of device malfunctions is remarkable. Certainly
prospective users and even participants in the study should
be aware that this is an issue even though most events were
related to external components and there were no serious
complications in this study.
It is expected, in a company-sponsored study regulated
by an IDE from the FDA and conducted by investigators
who believe in the merits of the technology, that bias of
various origins may influence the data. This is true for all
company-sponsored FDA-regulated device studies. It is also
impossible for the investigators to deal with unanticipated
questions that arise during the course of the study. Proving
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safety and efficacy basically means looking at survival,
pre-defined adverse events, and the function of the pump.
Dwelling on negative aspects that were not the focus of the
original study, especially in face of limited journal pages
and strict editing, is not done. We must hope that these
negative details faced each day by the investigators will be
dealt with individually in future reports. Further, much of
the design of the study is dictated by the FDA’s desire to
document adverse events that can be definitively related to
the device, hence the subjective division of complications
into categories that are easy targets for criticism. Can we
always definitively implicate the device or the patient and
the disease in bleeding, embolism, infection, end-organ
dysfunction, or even death? Obviously we cannot. The data
are often subjective and the reports are less than perfect.
We must base our decisions to support or oppose increas-
ing clinical use of artificial hearts on imperfect data. In the
end, it seems reasonable to interpret this and similar reports
from the perspective of the “big picture.” The device
pumped physiologic flows, allowed 67% of a selected group
of patients to survive to transplantation with an embolic
incidence of 11%, and led to out-of-hospital life for 41%.
Some provocative and very important questions of coagu-
lation/bleeding, infection, inflammation, and device dura-
bility were raised. These questions must be addressed, but
ideally not by studies that are company sponsored. In the
meantime, further use of the HeartMate vented electric
VAD is indicated.
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